ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ibrutinib

Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.

Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 14, 201774 company-led studies, 6 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only364 open or runningphase 4since Jun 14, 2017May 14, 2012Dec 31, 2026phase 3 · NCT01804686
AbbVie341 open or runningphase 4since Jun 5, 2017Feb 20, 2009May 10, 2027phase 4 · NCT03229200
Novartisits history only21 open or runningphase 2since May 21, 2019Mar 13, 2019Jun 30, 2027phase 2 · NCT03960840
BeOne Medicinesits history only10 open or runningphase 3since Feb 7, 2017Feb 7, 2017none ahead
Oncternal Therapeuticsits history only10 open or runningphase 3since Jun 9, 2022Jun 9, 2022none ahead

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Feb 20, 2009.

  1. Oct 1, 2014Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02264574 · 229 enrolled · United States, Australia, Austria and more
  2. Jan 16, 2015Phase 2 study in Leukemia, Myeloid, AcuteNCT02351037 · 36 enrolled · United States
  3. May 4, 2015Phase 3 study in Metastatic Pancreatic AdenocarcinomaNCT02436668 · 430 enrolled · United States, Belgium, France and more
  4. Sep 3, 2015Phase 2 study in Multiple MyelomaNCT02548962 · 11 enrolled · United States, Australia, Czechia and more
  5. Nov 4, 2015Phase 2 study in Carcinoma, Renal CellNCT02599324 · 263 enrolled · United States, Korea, Republic of, Spain and more
  6. Aug 19, 2016Phase 2 study in Multiple MyelomaNCT02902965 · 74 enrolled · Czechia, Germany, Greece and more
  7. Sep 20, 2016Phase 2 study in LeukemiaNCT02910583 · 323 enrolled · United States, Australia, Italy and more
  8. Oct 25, 20162 phase 3 studiesNCT02959944, NCT02947347
  9. Jun 5, 2017Phase 4 study in Lymphoma, B-CellNCT03229200 · 297 enrolled · United States, Australia, Canada and more
  10. Dec 12, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeNCT03790332 · 59 enrolled · United States, Australia, Austria and more
  11. Mar 12, 2019Phase 2 study in LeukemiaNCT03873493 · 14 enrolled · United States, Australia, Austria and more
  12. May 4, 2020Phase 2 study in COVID-19NCT04375397 · 46 enrolled · United States
  13. Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellNCT04477486 · 13 enrolled · Japan
  14. Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05105841 · 20 enrolled · Japan

Ahead

  1. May 10, 2027Primary completion: phase 4 study in Lymphoma, B-CellNCT03229200

TargetBeta

BTK →read by rule
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 34 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan2CompletedOct 9, 202520
NCT04477486Lymphoma, Mantle-Cell · Japan2CompletedFeb 9, 202213
NCT04375397COVID-19 · United States2CompletedMay 10, 202146
NCT03873493Leukemia · United States, Australia, Austria and more2CompletedNov 4, 202114
NCT03790332Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more2CompletedOct 9, 202559
NCT03229200Lymphoma, B-Cell · United States, Australia, Canada and more4Active, not recruitingMay 10, 2027297
NCT02947347Lymphoma, Follicular · United States, Australia, Austria and more3CompletedFeb 21, 2024445
NCT02959944Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more3CompletedMar 27, 2020193
NCT02910583Leukemia · United States, Australia, Italy and more2CompletedNov 12, 2020323
NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more2CompletedOct 26, 201874
NCT02599324Carcinoma, Renal Cell · United States, Korea, Republic of, Spain and more2CompletedAug 20, 2021263
NCT02548962Multiple Myeloma · United States, Australia, Czechia and more2TerminatedJun 13, 201811
NCT02436668Metastatic Pancreatic Adenocarcinoma · United States, Belgium, France and more3CompletedOct 2018430
NCT02351037Leukemia, Myeloid, Acute · United States2TerminatedApr 201736
NCT02264574Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more3CompletedMar 26, 2018229
NCT02195869Graft vs Host Disease · United States2CompletedSep 15, 201745
NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more3CompletedNov 7, 2019181
NCT02142049Lymphoma · United States2CompletedAug 201735
NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more2CompletedDec 17, 2020138
NCT01980628Lymphoma, B-Cell, Marginal Zone · United States, Belgium, France and more2CompletedJul 201663
NCT01980654Lymphoma, Follicular · United States2CompletedNov 201780
NCT01962792Multiple Myeloma · United States, Canada2CompletedMar 201984
NCT01744691Chronic Lymphocytic Leukemia With 17p Deletion · United States, Australia, Belgium and more2CompletedJun 2014145
NCT01724346Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedAug 18, 2023269
NCT01722487Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more3CompletedMay 2015269
NCT01578707Recurrence · United States, Australia, Austria and more3CompletedNov 2013391
NCT01478581Multiple Myeloma · United States2CompletedAug 201892
NCT01325701Lymphoma, Large B-Cell, Diffuse · United States2CompletedOct 201478
NCT01292135Leukemia, Lymphocytic, Chronic, B-Cell · United States1CompletedNov 201233
NCT01236391Lymphoma, Mantle-Cell · United States, Germany, Poland and more2CompletedJan 2014115
NCT01217749Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedJun 201371
NCT01109069Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedApr 26, 2019199
NCT01105247Leukemia, Lymphocytic, Chronic, B-Cell · United States2CompletedDec 2012133
NCT00849654Lymphoma, B-Cell · United States1CompletedJul 201266

How it is read

Names in the registry

  • “Ibrutinib”, 49 entries
  • “PCI-32765”, 10 entries
  • “ibrutinib”, 6 entries
  • “PCI-32765 (Ibrutinib)”, 2 entries
  • “SNX-5422 plus ibrutinib”, 2 entries

Codes read as this program: PCI32765.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.